Sarilumab shows promise in treatment of noninfectious uveitis of posterior segment
Subcutaneous sarilumab shows therapeutic potential in the management of noninfectious uveitis affecting the posterior segment of the eye, especially eyes with uveitic macular oedema, according to the results of the phase II SATURN trial.
SATURN randomly assigned (2:1) 58 eyes of adult patients with noninfectious intermediate, posterior or panuveitis to treatment with subcutaneous sarilumab 200 mg or placebo administered every other day for 16 weeks.
At week 16, the primary endpoint of proportion of patients with ≥2-step reduction in vitreous haze (VH) did not significantly differ between the sarilumab and placebo arms (mean, 46.1 percent vs 30.0 percent; p=0.2354). The alternate primary endpoint of corticosteroid dose <10 mg/day was better in the former arm (mean, 64.0 percent vs 35.0 percent; p=0.0372).
In the subgroup of eyes VH grade 2 or higher at baseline, VH decreased significantly with sarilumab vs placebo at week 16 regardless of assessment by central reading centre (mean, –2.1 vs –1.7; p=0.0255) or investigator (–2.5 vs –1.2; p=0.0170).
Sarilumab was also superior to placebo in terms of mean best-corrected visual acuity gain from baseline to week 16 in the overall population (8.9 vs 3.6 letters; p=0.0333) and in the subgroup of eyes with central subfield thickness (CST) ≥300 μm at baseline (12.2 vs 2.1 letters; p=0.0517). Corresponding changes in CST were –46.8 vs 2.6 μm (p=0.0683) in the overall population and –112.5 vs –1.8 μm (p=0.1317) in the subgroup of eyes with CST ≥300 μm at baseline, respectively.
Commonly reported ocular adverse events included worsening of uveitis and retinal infiltrates.